期刊
JOURNAL OF WOMENS HEALTH
卷 21, 期 4, 页码 456-462出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jwh.2011.3009
关键词
-
类别
资金
- Penn Clinical Pharmacogenomic Epidemiology pilot grant [5P20RR020741]
- National Institutes of Health (NIH) [R21 AT004695, 1 K23 AT004112-03, HD-058799-01]
- Clinical and Translational Research Center at the University of Pennsylvania [807602]
- Doris Duke Clinical Research Foundation
- American Cancer Society (ACS) [CCCDA-08-107-02, MRSG-08-110-01-CCE]
Purpose: Breast cancer survivors (BCS) taking aromatase inhibitors (AIs) are at an increased risk for decreased bone density and fractures. Given the role vitamin D plays in bone metabolism, we examined the prevalence of and risk factors for vitamin D deficiency in a study of postmenopausal BCS on AIs. Methods: We collected data on 391 postmenopausal women with stage I-III breast cancer on AI therapy. Vitamin D levels were measured by radioimmunoassay from patients' sera; deficiency was defined as a level < 30 ng/mL. Multivariate models were created to assess risk factors for deficiency. Results: The median vitamin D level was 35 ng/mL (range 6.78-93.15), and 35% of women were vitamin D deficient. When adjusting for age and vitamin D supplementation, minority participants were more likely to be vitamin D deficient than white women, (adjusted odds ratio [AOR] 2.18, 95% confidence interval [CI] 1.22-3.89, p = 0.009). Both overweight (AOR 3.05, 95% CI 1.72-5.41, p < 0.001) and obese participants (AOR 3.21, 95% CI 1.79-5.78, p < 0.001) had higher deficiency rates than did normal weight participants. Conclusions: Hypovitaminosis D is common in BCS, and those who are nonwhite or overweight are at a higher risk of deficiency despite taking vitamin D supplements.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据